You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
The agents will be tested in rodent models of cancer and, if<br />
successful, will open novel therapeutic opportunities for the<br />
selective treatment of superfi cial tumors in accessible body<br />
cavities.<br />
Expected results<br />
Most importantly, there is a reasonable expectation of a medical<br />
benefi t for cancer patients stemming both directly and<br />
indirectly from this project:<br />
• directly, since immuno-PDT procedures promise to be<br />
invaluable for the selective ablation of inoperable superfi<br />
cial neoplastic lesions, such as certain head&neck,<br />
gastrointestinal, urogenital and gynecological tumours;<br />
• indirectly, since the knowledge generated by the validation<br />
of novel antibodies for vascular targeting applications is<br />
likely to have an impact in other forms of immunotherapy,<br />
including the use of full IgGs and antibody-cytokine fusions<br />
for cancer therapy.<br />
Potential applications<br />
When considering immuno-PDT applications in oncology in<br />
a strict sense, the potential market is directly determined by<br />
the incidence of inoperable superfi cial neoplastic lesions,<br />
such as certain head&neck, gastrointestinal, urogenital and<br />
gynecological tumors, which would benefi t from a PDTbased<br />
ablation.<br />
In a broader sense, discoveries in terms of new tumour targets,<br />
new antibodies, new coupling methodologies and new<br />
photosensitisers will benefi t several areas of biomedical<br />
development, including non-oncological indications such as<br />
potentially-blinding angiogenesis-related ocular disorders<br />
(age-related macular degeneration, diabetic retinopathy).<br />
212<br />
Coordinators<br />
Chiara Falciani<br />
Reinerio Gonzalez<br />
Philogen<br />
Siena, Italy<br />
chiara.falciani@philogen.it<br />
reinerio.gonzalez@philogen.it<br />
Partners<br />
Ross Boyle<br />
University of Hull<br />
Hull, United Kingdom<br />
Gokhan Yahioglu<br />
Photobiotics<br />
London, United Kingdom<br />
Project number<br />
LSHC-CT-2006-37489<br />
EC contribution<br />
€ 3 000 000<br />
Duration<br />
36 months<br />
Starting date<br />
01/10/2006<br />
Instrument<br />
STREP – SME<br />
Project website<br />
www.immunopdt.net<br />
Luciano Zardi<br />
Centro Biotecnologie Avanzate<br />
Genova, Italy<br />
Dario Neri<br />
Swiss Federal Institute of Technology<br />
Zurich, Switzerland<br />
Peter Vajkoczy<br />
University of Heidelberg<br />
Heidelberg, Germany<br />
Mahendra Deonarain<br />
Imperial College London<br />
London, United Kingdom<br />
Christina Kousparou<br />
Trojantec<br />
Nicosia, Cyprus<br />
CANCER RESEARCH PROJECTS FUNDED UNDER THE SIXTH FRAMEWORK PROGRAMME
Change language